Xbrane Biopharma AB
7XB
Company Profile
Business description
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane’s product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration.
Contact
Retzius vag 8
Solna171 65
SWET: +46 760346733
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
65
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,148.90 | 93.60 | 1.16% |
| CAC 40 | 8,082.57 | 88.90 | -1.09% |
| DAX 40 | 22,944.59 | 343.47 | -1.47% |
| Dow JONES (US) | 41,964.63 | 383.32 | 0.92% |
| FTSE 100 | 8,689.33 | 17.33 | -0.20% |
| HKSE | 24,219.95 | 551.19 | -2.23% |
| NASDAQ | 17,750.79 | 246.67 | 1.41% |
| Nikkei 225 | 37,751.88 | 93.54 | -0.25% |
| NZX 50 Index | 12,054.72 | 8.79 | 0.07% |
| S&P 500 | 5,675.29 | 0.00 | 0.00% |
| S&P/ASX 200 | 7,918.90 | 90.60 | 1.16% |
| SSE Composite Index | 3,408.95 | 17.48 | -0.51% |